Disufenton sodium (Cerovive)

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 200721

CAS#: 168021-79-2 (sodium)

Description: Disufenton sodium, also known as Cerovive, OKN007, NXY-059, is a disulfonyl derivative of phenyl-tert-butyl nitrone (PBN), with potential anti-glioma activity. Although the exact mechanism(s) of action of OKN007 are still largely unknown, this agent appears to inhibit cancer cell proliferation and migration. This agent appears to inhibit the activity of sulfatase 2 (SULF2), a highly specific endoglucosamine-6-sulfatase that is overexpressed in the extracellular matrix of cancer cells and catalyzes the removal of sulfate from the 6-O-sulfate esters of heparin.

Price and Availability


USD 150
USD 1250

USD 350
USD 3650

USD 850
USD 5650

Disufenton sodium (Cerovive), purity > 98%, is in stock. The same day shipping out after order is received. Note: the estimated shipping out time for order > 2.5g may be 2 weeks..

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 200721
Name: Disufenton sodium (Cerovive)
CAS#: 168021-79-2 (sodium)
Chemical Formula: C11H13NNa2O7S2
Exact Mass:
Molecular Weight: 381.33
Elemental Analysis: C, 34.65; H, 3.44; N, 3.67; Na, 12.06; O, 29.37; S, 16.82

Related CAS #: 168021-79-2 (sodium)   168021-77-0 (free acid)    

Synonym: NXY059; NXY 059; NXY-059; CXY 059; CXY059; CXY-059; OKN007; OKN-007; OKN 007; ARL 16556; ARL16556; ARL-16556; CPI-22; CPI22; CPI 22; Disufenton sodium

IUPAC/Chemical Name: sodium (Z)-4-((tert-butyloxidoazanylidene)methyl)benzene-1,3-disulfonate


InChi Code: InChI=1S/C11H15NO7S2.2Na/c1-11(2,3)12(13)7-8-4-5-9(20(14,15)16)6-10(8)21(17,18)19;;/h4-7H,1-3H3,(H,14,15,16)(H,17,18,19);;/q;2*+1/p-2/b12-7-;;

SMILES Code: O=S(C1=CC=C(/C=[N+](C(C)(C)C)\[O-])C(S(=O)([O-])=O)=C1)([O-])=O.[Na+].[Na+]

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>5 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:

Additional Information



1: Lapchak PA, McKim JM Jr. CeeTox™ Analysis of CNB-001 a Novel Curcumin-Based Neurotrophic/Neuroprotective Lead Compound to Treat Stroke: Comparison with NXY-059 and Radicut. Transl Stroke Res. 2011 Mar;2(1):51-59. PubMed PMID: 21494575; PubMed Central PMCID: PMC3074116.

2: Culot M, Mysiorek C, Renftel M, Roussel BD, Hommet Y, Vivien D, Cecchelli R, Fenart L, Berezowski V, Dehouck MP, Lundquist S. Cerebrovascular protection as a possible mechanism for the protective effects of NXY-059 in preclinical models: an in vitro study. Brain Res. 2009 Oct 19;1294:144-52. doi: 10.1016/j.brainres.2009.07.035. Epub 2009 Jul 23. PubMed PMID: 19631615.

3: Bath PM, Gray LJ, Bath AJ, Buchan A, Miyata T, Green AR; NXY-059 Efficacy Meta-analysis in Individual Animals with Stroke Investigators. Effects of NXY-059 in experimental stroke: an individual animal meta-analysis. Br J Pharmacol. 2009 Aug;157(7):1157-71. doi: 10.1111/j.1476-5381.2009.00196.x. Epub 2009 Apr 27. PubMed PMID: 19422398; PubMed Central PMCID: PMC2743834.

4: Cheng YF, Jiang J, Hu P, Reinholdsson I, Guo W, Asenblad N, Nilsson D. Pharmacokinetics of 8-hour intravenous infusion of NXY-059: a phase I, randomized, double-blind (within dose panels), placebo-controlled study in healthy Chinese volunteers. Clin Ther. 2008 Dec;30(12):2342-53. doi: 10.1016/j.clinthera.2008.12.013. PubMed PMID: 19167593.

5: Clausen F, Marklund N, Lewén A, Hillered L. The nitrone free radical scavenger NXY-059 is neuroprotective when administered after traumatic brain injury in the rat. J Neurotrauma. 2008 Dec;25(12):1449-57. doi: 10.1089/neu.2008.0585. PubMed PMID: 19118455.

6: Savitz SI. Cosmic implications of NXY-059. Stroke. 2009 Mar;40(3 Suppl):S115-8. doi: 10.1161/STROKEAHA.108.535112. Epub 2008 Dec 8. PubMed PMID: 19064771.

7: Macleod MR, van der Worp HB, Sena ES, Howells DW, Dirnagl U, Donnan GA. Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality. Stroke. 2008 Oct;39(10):2824-9. doi: 10.1161/STROKEAHA.108.515957. Epub 2008 Jul 17. PubMed PMID: 18635842.

8: Diener HC, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, Shuaib A, Ashwood T, Wasiewski W, Alderfer V, HÃ¥rdemark HG, Rodichok L; SAINT I and II Investigators. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke. 2008 Jun;39(6):1751-8. doi: 10.1161/STROKEAHA.107.503334. Epub 2008 Mar 27. PubMed PMID: 18369171.

9: Savitz SI, Fisher M. NXY-059 for the treatment of stroke. N Engl J Med. 2007 Nov 22;357(21):2198; author reply 2198-9. PubMed PMID: 18032772.

10: Mutch NJ, Moore NR, Mattsson C, Jonasson H, Green AR, Booth NA. The use of the Chandler loop to examine the interaction potential of NXY-059 on the thrombolytic properties of rtPA on human thrombi in vitro. Br J Pharmacol. 2008 Jan;153(1):124-31. Epub 2007 Nov 5. PubMed PMID: 17982476; PubMed Central PMCID: PMC2199381.